Stugeron is developed by Chulalongkorn University.

What development phase is Stugeron in?

Stugeron is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Stugeron

Chulalongkorn University · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Stugeron
Sponsor	Chulalongkorn University
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo (PHASE4)
Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism (NA)
Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis (PHASE4)
A Double-blind Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Stugeron CI brief — competitive landscape report
Stugeron updates RSS · CI watch RSS
Chulalongkorn University portfolio CI